WuXi Biologics (Cayman) Price, Forecast, Insider, Ratings, Fundamentals & Signals

The company demonstrated a deep commitment to achieving esg success in partnership with global clients, creating long-term value for all stakeholders. the company made remarkable progress in tackling climate change, achieving a 29% intensity reduction of scope 1 and scope 2 greenhouse gas emissions in 2023 since 2020.

Hong kong, march 26, 2024 /prnewswire/ -- wuxi biologics (cayman) inc. ("wuxi biologics" or "the group", stock code: 2269.hk), a leading global contract research, development and manufacturing organization (crdmo) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended december 31, 2023 ("reporting period").

Shanghai , march 22, 2024 /prnewswire/ -- wuxi biologics ("wuxi bio") (2269.hk), a leading global contract research, development and manufacturing organization (crdmo), announced it has been recognized for leadership in corporate transparency and performance on water security by the environmental non-profit cdp, securing a place on its annual 'a list'. based on data reported through cdp's 2023 questionnaire, wuxi biologics achieved a score of 'a' in the water security category, ranking it in the top 2% of the more than 23,000 companies evaluated.

Shanghai , march 5, 2024 /prnewswire/ -- wuxi biologics ("wuxi bio") (2269.hk), a leading global contract research, development and manufacturing organization (crdmo), announced it has been recognized for outstanding performance in the 2023 climate change assessment conducted by the global environmental non-profit cdp, achieving the leadership level with a score of "a-". cdp runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact.

Named top-rated for fourth consecutive year committed to generating long-term value for all stakeholders shanghai , feb. 21, 2024 /prnewswire/ -- wuxi biologics ("wuxi bio") (2269.hk), a leading global contract research, development and manufacturing organization (crdmo), announced it has been recognized as a 2024 industry top-rated and regional top-rated company by morningstar sustainalytics' environmental, social and governance (esg) ratings, marking the fourth consecutive year the company has achieved this honor. sustainalytics is a leading esg data, research, and ratings firm that supports global investors with the development and implementation of responsible investment strategies.

WuXi Biologics Cayman Inc., one of China's leading drug contract research and manufacturing companies, said its chief executive officer has not worked for any military-affiliated institution. The stock was hammered in Hong Kong on Friday following the news that proposed US legislation would ban the company from American government contracts.

WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite the temporary issues, WuXi Biologics remains a great company with fast growth, profitability, and a solid financial foundation.

China-headquartered WuXi XDC, the contract medical researching unit of WuXi Biologics (Cayman) , said on Tuesday it intended to raise up to HK$3.68 billion ($470.56 million) in one of Hong Kong's top initial public offerings (IPO) this year.

WuXi Biologics said in a statement on Tuesday on WeChat that two of its subsidiaries being put on the U.S. Commerce Department's "unverified list" will have no impact on its business or services to partners.

The declines come after the Financial Times reported that the U.S. Commerce Department on Thursday is expected to place some Chinese companies involved in biotechnology on its entity list, which is designed to limit access to key U.S. exports.

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases. High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments.

SHANGHAI and ROCKVILLE, Md., May 26, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.

SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has been recognized as the grand winner of the Bioprocessing Excellence in Greater China Region Award in two prestigious categories: the Bioprocessing Excellence in Antibody & ADC Therapeutics Manufacturing in Greater China Region and the Bioprocessing Excellence in Viral Clearance and Safety in Greater China Region at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2021.  Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality across Asia and the rest of the world.

WUXI, China, April 6, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). The inspections focused on the two different innovative biologics manufactured at the company's facilities including MFG1, MFG2 and DP1 in Wuxi, China.

SUZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90% interest of CMAB Biopharma Group ("CMAB"). The transaction is expected to close in the second quarter of 2021.